Mae Zakhour
Gynecologic Oncology · Grand Rapids, MINPI 1427342294
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,560 of the $4,855 with a category attached, or 73.3%. 11 manufacturers reported payments, led by AstraZeneca at 53.3% of the total. 2025 is the largest year on record at $2,585, 7.8 times the $331 reported in 2019.
Across 19 payments — averaging $255.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Seagen Inc.$1K
- GSK$393
- Myriad Genetic Laboratories, Inc.$184
- Eisai Inc.$109
- Genentech USA, Inc.$102
- plus $261 from 5 others
Across 34 payments — averaging $3697.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$87K
- Merck$36K
- Pfizer$3K
- Incyte Corporation$643
What the payments were for
- Consulting fees$3,56073%
- Food & beverage$1,23025%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $2,586 |
| Seagen Inc. | 3 | $1,220 |
| GSK | 5 | $393 |
| Myriad Genetic Laboratories, Inc. | 2 | $184 |
| Eisai Inc. | 1 | $109 |
| Genentech USA, Inc. | 1 | $102 |
| Immunogen, Inc. | 1 | $70 |
| Pfizer | 1 | $65 |
| Clovis Oncology, Inc. | 1 | $65 |
| Tesaro, Inc. | 1 | $39 |
| Aadi Bioscience, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PreciseTumor$141
- LYNPARZA$126
- JEMPERLI$125
- Avastin$102
How this compares
$4,855 in reported general payments places this provider in the 75th percentile of 43 gynecologic oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $6,638 |
| Anastrozole | 23 | $1,486 |
| Prochlorperazine Maleate | 49 | $502 |
| Letrozole | 12 | $444 |
| Ondansetron Hcl | 31 | $150 |
| Olanzapine | 23 | $132 |
| Prednisone | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Grand Rapids
- Leigh SeamonGrand Rapids$3K
- Christopher HummelGrand Rapids$866
- Margaret WhickerGrand Rapids$299
- Charles HarrisonGrand Rapids$178
- Robert MorrisDetroit$807K
- Ira WinerDetroit$25K
- Morgan TaylorDetroit$23K
- Radhika GogoiDetroit$12K
- Douglas PugmireRochester Hills$9K
- Zaid Al-WahabGrosse Pointe$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.